Heartbeam

Heartbeam P/B

The P/B (Price-to-Book Ratio) of Heartbeam (BEAT) as of Oct 22, 2026 is 19.73. In the previous year, P/B (Price-to-Book Ratio) was 31.05 — a change of -36.46% (lower).

P/B

19.73

YoY

-36.46%

Last updated:

P/B (Price-to-Book Ratio) of Heartbeam is 2025 19.73 . P/B (Price-to-Book Ratio) of Heartbeam was 2024 31.05 . It decreases by -36.46% lower compared to the previous year.

The Heartbeam P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
0.17 USD
Jan 1, 2019
-13.78 USD
Jan 1, 2020
-10.73 USD
Jan 1, 2021
3.83 USD
Jan 1, 2022
21.63 USD
Jan 1, 2023
3.22 USD
Jan 1, 2024
31.05 USD
Jan 1, 2025
19.73 USD
The Heartbeam P/B history
YEARP/BYoY
19.73-36.46%
31.05+863.54%
3.22-85.10%
21.63+464.87%
3.83-135.68%
-10.73-22.11%
-13.78-8,430.69%
0.17-19.24%
0.20-44.60%
0.37-45.34%
0.68-16.13%
0.81—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Heartbeam Stock analysis

What does Heartbeam do? HeartBeam, Inc. generates revenue through its proprietary VECG technology platform, which includes two patented products: HeartBeam AIMI and HeartBeam AIMIGo. HeartBeam AIMI is software designed for acute care settings, offering 3D comparison of baseline and symptomatic 12-lead ECG to detect heart attacks. HeartBeam AIMIGo is a credit card-sized 12-lead ECG device paired with a smartphone app and cloud-based diagnostic software for remote heart attack detection. The company targets healthcare facilities and remote monitoring segments, focusing on cardiovascular diagnostic solutions for both in-hospital and out-of-hospital settings. HeartBeam AIMI is sold to acute care providers such as hospitals and emergency departments, while HeartBeam AIMIGo serves patients and remote healthcare services seeking continuous cardiac monitoring. The firm's revenue streams derive from the commercialization of these two products, leveraging its patented VECG technology to provide higher resolution ambulatory ECG solutions. The company's focus on detecting and monitoring cardiac disease outside traditional healthcare facilities drives its product development and sales strategy. HeartBeam Inc. operates in the cardiovascular diagnostic technology sector, with its products designed to enable cardiac disease detection both inside and outside healthcare facilities. The firm's VECG platform allows for 3D vector imaging of cardiac electrical activity, enhancing diagnostic capabilities beyond standard ECG methods. Revenue is generated through the sale of software, devices, and cloud-based diagnostic systems tailored to specific healthcare environments and remote monitoring needs. Heartbeam is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Heartbeam stock

P/B (Price-to-Book Ratio) of Heartbeam is 19.73 in 2025.

P/B (Price-to-Book Ratio) of Heartbeam changed from 31.05 to 19.73, representing a -36.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Heartbeam since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Heartbeam with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Heartbeam

All Key Metrics — Heartbeam